Rowook Park

Cooley advised Bridge to Life, an organ preservation and perfusion technologies supplier, on its sale of certain assets – including its EVOSS heart and lung and LifeCradle heart perfusion assets – to TransMedics.

Cooley advised CinCor Pharma, a clinical-stage biopharmaceutical company, on its definitive agreement to be acquired by AstraZeneca. M&A partners Rama Padmanabhan and Rowook Park and corporate partners Div Gupta and Sarah Sellers led the Cooley team.

A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.

Cooley advised Digital Shadows, a company that delivers threat intelligence for security teams, on its agreement to sell to ReliaQuest, a force multiplier of security operations, for $160 million. Partners Rowook Park and Erik Edwards, along with associates Bram Couvreur, Rajdeep Bains, Mary Wilbourn and Omed Sharifi, led the Cooley team advising Digital Shadows. 

Read more

Cooley advised ViaCyte, a biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for Type 1 diabetes (T1D), on its definitive agreement to be acquired by global biotechnology company Vertex Pharmaceuticals for $320 million in cash. Partners Rowook Park and Carlos Ramirez, along with associate Lindsey O’Crump, led the Cooley team advising ViaCyte.